RMTI logo

ROCKWELL MEDICAL INC

RMTINASDAQ
πŸ† #4522 by market capEarnings Nov 12US Equity
$7.21β–² $0.36 (+5.26%)
Pre-market Β· at close
πŸ””
Track RMTI
Get earnings, price moves & breaking news on Telegram
Track
24hβ–² 5.3%
7dβ–² 2.4%
14dβ–Ό 2.8%
30dβ–Ό 16.3%
ytdβ–Ό 11.1%
1yβ–Ό 33.5%
🏦Market Cap
$29M
Small Cap
πŸ“ˆRevenue Growth (YoY)
-21.1%
Declining
πŸ“ŠGross Margin
18.7%
Thin
πŸ’΅FCF Margin
5.3%
Moderate
βš–οΈP/S Ratio
0.4x
Cheap
Otter Score
β€”
Insufficient data

Trading Snapshot

Day Range
$6.80 – $7.35
52-Week Range
$4.89 – $12.90
Volume (shares)
1,027
Avg Volume (shares)
β€”
Shares Outstanding
4.0M
Next Earnings
2026-11-12

Fundamentals Snapshot

Annual Revenue
$69M
Last Q Revenue
$18M
P/E Ratio
β€”
P/S Ratio
0.4x
EPS (TTM)
$-1.33
Dividend Yield
β€”
Dilution (1yr)
+19.9%
RMTI logo

ROCKWELL MEDICAL INC

RMTI
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$69Mβ–Ό βˆ’31.8% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
16.9%β–Ό βˆ’2.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
βˆ’$5Mβ–Ό βˆ’871.5% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
βˆ’$1Mβ–Ό βˆ’137.6% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
3.9Mβ–² +19.9% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
βˆ’$2Mβ–Ό βˆ’$4M YoY
StockOtter Β· stockotter.space

About ROCKWELL MEDICAL INC

Rockwell Medical, Inc., together with its associated companies, operates as a biopharmaceutical firm specializing in treatments for chronic and end-stage kidney disease. The company provides a range of therapies and products aimed at addressing iron deficiency and supporting hemodialysis procedures, serving markets both within the United States and internationally. A key offering includes its Triferic line (Triferic Dialysate and Triferic AVNU), an innovative iron replacement therapy. This therapy is designed to replenish iron and maintain healthy hemoglobin levels in dialysis patients, notably without increasing existing iron stores. Beyond iron management, Rockwell Medical manufactures, sells, and distributes a comprehensive range of hemodialysis concentrates. These include various acid concentrates such as CitraPure (citric), Dri-Sate (dry), and RenalPure (liquid), alongside a dry acid concentrate mixer, and powder bicarbonate concentrates like RenalPure and SteriLyte. These crucial products are vital for sustaining life in dialysis patients by facilitating the removal of toxins and the replacement of essential nutrients in their bloodstream. The company further supplies ancillary items critical for hemodialysis procedures. This extensive catalog comprises blood tubing, fistula needles, dialyzers, pharmaceuticals, specialized component kits, dressings, cleaning agents, filtration salts, and other necessary provisions utilized by hemodialysis providers. Looking to the future, Rockwell Medical is actively developing additional therapeutic candidates. These include treatments for hospitalized individuals suffering from acute heart failure, as well as solutions for home infusion therapy, enabling patients to receive intravenous medications in a home setting. The company primarily serves medium and small-sized dialysis chains, as well as independent dialysis centers. Established in 1996, Rockwell Medical, Inc. maintains its corporate headquarters in Wixom, Michigan.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Insufficient data
β€”/100
Analyst data unavailable.

Latest News & Updates

News unavailable.